Published by Global Banking & Finance Review®
Posted on August 1, 2025
1 min readLast updated: January 22, 2026
Add as preferred source on GooglePfizer and BioNTech's appeal against Moderna's COVID-19 vaccine patent win was denied by London's Court of Appeal, affirming Moderna's entitlement to damages.
LONDON (Reuters) -Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed one of Moderna's patents at London's Court of Appeal.
Last year, the High Court ruled that one of Moderna's patents relating to the messenger RNA (mRNA) technology which underpinned its COVID-19 vaccine was valid and that Pfizer and BioNTech's Comirnaty vaccine had infringed it, meaning Moderna is entitled to damages in relation to sales after March 2022.
Pfizer and Moderna had appealed to try to overturn that decision, arguing Moderna's developments of mRNA technology were obvious developments of previous work, rendering the patent invalid.
(Reporting by Sam Tobin; Editing by Catarina Demony)
Pfizer and BioNTech lost their bid to overturn a ruling regarding patent infringement at London's Court of Appeal.
The dispute revolves around a patent related to messenger RNA (mRNA) technology, which is fundamental to Moderna's COVID-19 vaccine.
They argued that Moderna's developments of mRNA technology were obvious advancements of prior work, which should render the patent invalid.
Explore more articles in the Headlines category
